Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 18, 2018
Event: Entry into a Material Definitive Agreement (Equity Line of Credit).
Key Financial Metrics and Transaction Details
This filing details a financing arrangement rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Total Offering Capacity: Up to $32,500,000 in aggregate value of common stock.
- Initial Purchase: 3,376,554 shares at $0.74 per share, totaling $2,500,000.
- Remaining Capacity: Up to an additional $30,000,000 available over a 30-month term.
- Regular Purchase Limits: Up to 400,000 shares per business day (subject to price adjustments), with a maximum single purchase obligation of $1,500,000.
- Accelerated Purchase Option: Company may direct additional purchases up to 300% of the Regular Purchase amount or 30% of daily trading volume.
- Issuance for Consideration: 852,537 shares issued to Lincoln Park Capital Fund, LLC as consideration for entering the agreement (no cash proceeds).
- Ownership Cap: Lincoln Park cannot beneficially own more than 9.99% of the Company's common stock.
Material Changes and Transaction Structure
The Company entered into a Purchase Agreement and Registration Rights Agreement with Lincoln Park Capital Fund, LLC. This establishes an "equity line of credit" allowing the Company to sell shares at its sole discretion. The agreement includes a floor price mechanism, preventing sales if the closing price falls below a specified threshold. The Company retains the right to terminate the agreement at any time at no cost. The Company is restricted from entering into other variable rate transactions for 30 months following the agreement date.
Guidance, Outlook, and Risks
- Use of Proceeds: General corporate purposes, including product expansion and working capital.
- Regulatory Status: The offering is made pursuant to an effective shelf registration statement (Form S-3) declared effective on October 12, 2017.
- Risks/Contingencies: Sales are subject to conditions in the Purchase Agreement, including the 9.99% beneficial ownership limit and the floor price provision. If the Registration Statement becomes unavailable, the Company must file additional registration statements.
- Management Commentary: The filing does not contain specific forward-looking guidance on clinical trials or revenue projections beyond the stated use of proceeds.
Investor Verification Checklist
- Verify the specific "floor price" defined in the attached Purchase Agreement (Exhibit 10.1) to understand the downside protection for the investor.
- Confirm the current beneficial ownership percentage of Lincoln Park Capital Fund, LLC to assess remaining capacity under the 9.99% cap.
- Review the attached Registration Rights Agreement (Exhibit 10.2) for details on liquidity rights for the investor.
- Monitor future 8-K filings for actual "Regular" or "Accelerated" purchases to track dilution and capital raised.
- Check the Company's latest 10-Q or 10-K for actual cash flow and liquidity status, as this 8-K does not provide those figures.